Navigation Links
Sanofi Pasteur announces FDA approval of menactra meningococcal conjugate vaccine indication for infants
Date:4/25/2011

Swiftwater, PA April 22, 2011 - Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that the U.S. Food and Drug Administration (FDA) has granted licensure to expand the indication for its meningococcal conjugate vaccine, Menactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine), to include a two-dose schedule for infants and children 9 months through 23 months of age. This is the first U.S. approval of a meningococcal vaccine for this age group.

"Licensure of Menactra vaccine for infants as young as 9 months of age gives the opportunity to help protect infants against this potentially deadly disease when the likelihood of exposure supports a need for early protection," said Stephen I. Pelton, MD, Professor of Pediatrics and Epidemiology, Boston University Schools of Medicine and Public Health and Chief, section of Pediatric Infectious Diseases, Boston Medical Center.

Meningococcal disease is a rare but deadly disease caused by the bacterium Neisseria meningitidis. The disease can progress quickly and take the life of a child within 24 hours. Menactra vaccine was the first quadrivalent conjugate vaccine licensed in the United States for active immunization against meningococcal disease caused by the serogroups contained in the vaccine (A, C, Y and W-135). More than 36 million doses of Menactra vaccine have been distributed in the United States since its licensure in 2005.

The FDA approval of Menactra vaccine for infants was based on results of one Phase II and three Phase III modified single-blind, controlled, multicenter trials in which more than 3,300 infants from the United States received Menactra vaccine using a two-dose schedule, starting as young as 9 months of age. Results from these studies showed that 2 doses of Menactra vaccine given 3 months apart elicit a robust immune response against the serogroups included in the
'/>"/>

Contact: Amy Ba
Amy.ba@sanofipasteur.com
570-957-0717
Cooney Waters Group, Inc.
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Eggs Being Produced by Recall Farms Safe, if Pasteurized, Experts Say
2. Government of Canada announces results in fight to save women and children with malaria
3. Oxford Nanopore announces licence agreement with Harvard University for graphene DNA sequencing
4. Elsevier Health Middle East announces publication of first bilingual medical title
5. International Vaccine Institute announces launch of Dengue Vaccine Initiative
6. Washington Life Sciences Discovery Fund announces grants to commercialize promising technologies
7. MSD Wellcome Trust Hilleman Laboratories announces first project
8. AIUM announces ultrasound practice accreditation in fetal echocardiography
9. American Physical Society announces Physical Review X
10. Beth Israel Deaconess Medical Center announces new AAAS Fellows
11. NARSAD announces $12.6 million for new generation of brain and behavior research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... (PRWEB) November 28, 2014 Earlier ... reported during the hugely popular, 2014 MTV Video ... organization Truth launched ground-breaking celebrity centered television advertisements ... MTV viewership figures were estimated by Entertainment ... ads placed the spotlight on celebrities photographed by ...
(Date:11/28/2014)... New York (PRWEB) November 28, 2014 ... http://www.consumerinjurylawyers.com/stryker-rejuvenate/stryker-hip-lawsuits/ ) have now been filed in a ... recalled metal implants, Bernstein Liebhard LLP reports. ... in Bergen County Superior Court reflects the filing ... II modular-neck hip stems, which were voluntarily recalled ...
(Date:11/28/2014)... a leader in the wig industry, has announced a great ... promotion features: , > 400 pieces of FOUR ... (no coupon code needed), > 10% off for ... $49 , Visit http://www.uniwigs.com for more details , The ... 1st and the first 100 shoppers each day will receive our ...
(Date:11/28/2014)... November 28, 2014 Patten Pecans, based ... grown. With those passions driving them, they've added a ... Having tried other pecans oils, they've found this ... to be exceptionally flavorful, retaining the buttery pecan notes ... nutritional benefits found in pecans nuts is ...
(Date:11/28/2014)... 28, 2014 An inventor from Flint, Mich., ... day. "I got this idea while lying in a hospital ... he said. , The Bed Buddy provides a more ergonomic ... the bathroom. It eliminates the need to leave the bed, ... and dignity. Easy to use and producible in design variations, ...
Breaking Medicine News(10 mins):Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 2Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 4Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 5Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 2Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 3Health News:Pre-X'mas Crazy Sale Starts from $0 at UniWigs.com 2Health News:Patten Pecans Goes Local with Nutritious Georgia Pecan Oil 2
... Carson M.D., professor of medicine and director of the Rebecca ... California, San Diego (UCSD) has identified a potent new anti-cancer ... South Pacific. The properties of somocystinamide A (ScA) are ... Proceedings of the National Academy of Science the week of ...
... A University of Alberta study recommends that workers on pig ... a child on a communal farm in Canada was diagnosed ... made a full recovery, health researchers were concerned because of ... multi-family community, who, fortunately, all demonstrated mild or no apparent ...
... $1 million, Five-year Grant, from New York State Department ... Becomes Lead,Poisoned, NEW YORK, Feb. 11 The ... at Montefiore,(CHAM) has been named one of three State ... regional healthcare delivery for children and,pregnant women with elevated ...
... lead to less controversial method of treating diseases , , ... they,ve reprogrammed human skin cells into ones with the ... that could aid in treating many diseases while sidestepping ... to become every cell type found in the human ...
... Inc.,(Nasdaq: NXXI ), the developer and marketer ... Iceland Health(R) brands that,help consumers manage blood sugar ... joint pain, today announced financial,results for the second ... 2007., The Company reported a 43% increase ...
... Feb. 11 Lincare Holdings,Inc. (Nasdaq: LNCR ), ... delivered to patients in the home, today announced,financial results ... 2007., For the quarter ended December 31, 2007, ... $368.1 million for the fourth quarter of,2006. The Company ...
Cached Medicine News:Health News:UCSD research team identifies novel anticancer drug from the sea 2Health News:Swine flu monitoring needed for farm workers, study says 2Health News:Montefiore Lead Poisoning Prevention ProgramNamed One of Three State Regional Resource Centers 2Health News:Scientists Reprogram Human Skin Cells Into Embryonic Stem Cells 2Health News:Scientists Reprogram Human Skin Cells Into Embryonic Stem Cells 3Health News:Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results 2Health News:Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results 3Health News:Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results 4Health News:Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results 5Health News:Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results 6Health News:Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results 7Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2007 Financial Results 2Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2007 Financial Results 3Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2007 Financial Results 4Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2007 Financial Results 5Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2007 Financial Results 6Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2007 Financial Results 7
(Date:11/26/2014)... 2014   Heska Corporation (NASDAQ: HSKA ... provider of advanced veterinary diagnostic and other specialty veterinary ... Chair, will attend The Benchmark Company, LLC,s Micro Cap Discovery ... be held at The Palmer House Hilton, 17 E. Monroe ... to 2:30 p.m. Please email hska@haydenir.com or contact ...
(Date:11/26/2014)... , Nov. 25, 2014  Array ... today announced that its Chief Executive Officer, ... the following upcoming conferences.  The public is ... webcasts on the Array BioPharma website:  ... 3, 2014Time:1:30 p.m.  Eastern Time Location: Palace ...
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 /PRNewswire/ ... AZN ) today announced that AMAGINE-2 TM , ... brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg ... were each shown to be superior to Stelara on the ...
Breaking Medicine Technology:Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... SAN FRANCISCO, Calif., May 16, 2012  Rigel Pharmaceuticals, Inc., ... franchise by focusing on two innovative, comprehensive treatment alternatives ... an inhaled SYK inhibitor, will be entering a Phase ... moderate asthmatic patients. The other, R256, an inhaled IL13 ...
... May 15, 2012   OphthaliX (OTCBB: OPLI) today ... ended March 31, 2012. OphthaliX is an advanced clinical-stage ... treatment of ophthalmic disorders.  Our drug, CF101 (known generically ... indications: dry eye syndrome; glaucoma and uveitis. We are ...
Cached Medicine Technology:Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease 2Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease 3Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease 4OphthaliX Reports First Quarter 2012 Financial Results 2OphthaliX Reports First Quarter 2012 Financial Results 3
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
Duraloc acetabular cup system....
... acetabular cup system has been designed to ... tri-spiked and cluster hole configurations. The objective ... micromotion on three primary modes: Tilt, migration ... features result in initial and long-term fixation. ...
Biopro rimmed acetabular is manufactured from titanium and is porous coated on the outside of its shell. The rimmed acetabular accommodates a polyethylene inert....
Medicine Products: